Search research articles
Contact Us
Filters
Showing results (51-60 of 95) with videos related to
Page
of 10
Sort By:
Journal of Hematopathology
|
June 13, 2019
Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
Julie Morscio, Emilie Bittoun, Nathalie Volders, et al.
Leukemia Research
|
March 6, 2012
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice
Antonio Salar, Corinne Haioun, Francesca G Rossi, et al.
Leukemia & Lymphoma
|
February 23, 2011
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study
Corinne Haioun, Antonio Salar, Ruth Pettengell, et al.
Plos One
|
September 23, 2014
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia
Monique Terwijn, Wendelien Zeijlemaker, Angèle Kelder, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Blood
|
February 18, 2011
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
Katrien Van Roosbroeck, Luk Cox, Thomas Tousseyn, et al.
Haematologica
|
February 11, 2017
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP <i>versus</i> R-CHOP in the phase 3 LYM-3002 study
Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Cancer Immunology, Immunotherapy : CII
|
April 27, 2020
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy
Lukas Marcelis, Asier Antoranz, Anne-Marie Delsupehe, et al.
Blood
|
August 23, 2003
Cladribine therapy for systemic mastocytosis
Hanneke C Kluin-Nelemans, J Marja Oldhoff, Jasper J Van Doormaal, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 95) with videos related to
Sort By:
Page
of 10
Journal of Hematopathology
|
June 13, 2019
Correction to: Secondary B-cell lymphoma associated with the Epstein-Barr virus in chronic lymphocytic leukemia patients
Julie Morscio, Emilie Bittoun, Nathalie Volders, et al.
Leukemia Research
|
March 6, 2012
The need for improved neutropenia risk assessment in DLBCL patients receiving R-CHOP-21: findings from clinical practice
Antonio Salar, Corinne Haioun, Francesca G Rossi, et al.
Leukemia & Lymphoma
|
February 23, 2011
Anemia and erythropoiesis-stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ± rituximab chemotherapy: results from an observational study
Corinne Haioun, Antonio Salar, Ruth Pettengell, et al.
Plos One
|
September 23, 2014
Leukemic stem cell frequency: a strong biomarker for clinical outcome in acute myeloid leukemia
Monique Terwijn, Wendelien Zeijlemaker, Angèle Kelder, et al.
Leukemia & Lymphoma
|
November 3, 2020
Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202)
Morton Coleman, David Belada, René-Olivier Casasnovas, et al.
Blood
|
February 18, 2011
JAK2 rearrangements, including the novel SEC31A-JAK2 fusion, are recurrent in classical Hodgkin lymphoma
Katrien Van Roosbroeck, Luk Cox, Thomas Tousseyn, et al.
Haematologica
|
February 11, 2017
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP <i>versus</i> R-CHOP in the phase 3 LYM-3002 study
Gregor Verhoef, Tadeusz Robak, Huiqiang Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
July 8, 2009
Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma
Georg Hess, Raoul Herbrecht, Jorge Romaguera, et al.
Cancer Immunology, Immunotherapy : CII
|
April 27, 2020
In-depth characterization of the tumor microenvironment in central nervous system lymphoma reveals implications for immune-checkpoint therapy
Lukas Marcelis, Asier Antoranz, Anne-Marie Delsupehe, et al.
Blood
|
August 23, 2003
Cladribine therapy for systemic mastocytosis
Hanneke C Kluin-Nelemans, J Marja Oldhoff, Jasper J Van Doormaal, et al.
Page
of 10